Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings.
BNT162 Vaccine
/ administration & dosage
Feasibility Studies
Female
Graft Rejection
/ immunology
Graft Survival
HLA Antigens
/ immunology
Hematopoietic Stem Cell Transplantation
Histocompatibility
Humans
Immunity, Humoral
Immunogenicity, Vaccine
Immunosuppressive Agents
/ therapeutic use
Kidney Failure, Chronic
/ diagnosis
Kidney Transplantation
Living Donors
Male
Middle Aged
Pilot Projects
Siblings
Time Factors
Transplantation Tolerance
Treatment Outcome
Vaccination
Vaccine Efficacy
COVID - 19
chimerism
hematopoietic stem cell transplantation (HSCT)
immunocompetence
kidney transplantation
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
10
2021
accepted:
05
01
2022
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
Induction of immunological tolerance has been the holy grail of transplantation immunology for decades. The only successful approach to achieve it in patients has been a combined kidney and hematopoietic stem cell transplantation from an HLA-matched or -mismatched living donor. Here, we report the first three patients in Europe included in a clinical trial aiming at the induction of tolerance by mixed lymphohematopoietic chimerism after kidney transplantation. Two female and one male patient were transplanted with a kidney and peripherally mobilized hematopoietic stem cells from their HLA-identical sibling donor. The protocol followed previous studies at Stanford University: kidney transplantation was performed on day 0 including induction with anti-thymocyte globulin followed by conditioning with 10x 1.2 Gy total lymphoid irradiation and the transfusion of CD34+ cells together with a body weight-adjusted dose of donor T cells on day 11. Immunosuppression consisted of cyclosporine A and steroids for 10 days, cyclosporine A and mycophenolate mofetil for 1 month, and then cyclosporine A monotherapy with tapering over 9-20 months. The 3 patients have been off immunosuppression for 4 years, 19 months and 8 months, respectively. No rejection or graft-versus-host disease occurred. Hematological donor chimerism was stable in the first, but slowly declining in the other two patients. A molecular microscope analysis in patient 2 revealed the genetic profile of a normal kidney. No relevant infections were observed, and the quality of life in all three patients is excellent. During the SARS-CoV-2 pandemic, all three patients were vaccinated with the mRNA vaccine BNT162b2 (Comirnaty
Identifiants
pubmed: 35173720
doi: 10.3389/fimmu.2022.796456
pmc: PMC8841472
doi:
Substances chimiques
HLA Antigens
0
Immunosuppressive Agents
0
BNT162 Vaccine
N38TVC63NU
Banques de données
ClinicalTrials.gov
['NCT00365846']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
796456Informations de copyright
Copyright © 2022 Fehr, Hübel, de Rougemont, Abela, Gaspert, Güngör, Hauri, Helmchen, Linsenmeier, Müller, Nilsson, Riesterer, Scandling, Schanz and Cippà.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996467
Am J Transplant. 2017 Nov;17(11):2851-2862
pubmed: 28449409
Blood. 2010 Feb 11;115(6):1280-7
pubmed: 20007805
Kidney Int. 2018 Oct;94(4):650-652
pubmed: 30243307
Nature. 1953 Oct 3;172(4379):603-6
pubmed: 13099277
N Engl J Med. 2008 Jan 24;358(4):362-8
pubmed: 18216356
Blood. 2013 Aug 29;122(9):1669-77
pubmed: 23869083
Am J Transplant. 2005 Jun;5(6):1237-47
pubmed: 15888027
Am J Transplant. 2019 Feb;19(2):324-330
pubmed: 30133954
Transplantation. 2021 May 1;105(5):935-940
pubmed: 33901128
Sci Transl Med. 2012 Mar 7;4(124):124ra28
pubmed: 22399264
Hum Immunol. 2018 May;79(5):272-276
pubmed: 29409743
Am J Transplant. 2015 Mar;15(3):695-704
pubmed: 25693475
Transplant Rev (Orlando). 2009 Jan;23(1):19-24
pubmed: 19027614
Eur J Immunol. 2005 Sep;35(9):2679-90
pubmed: 16082727
Hum Immunol. 2018 May;79(5):322-333
pubmed: 29374560
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
N Engl J Med. 2021 Aug 19;385(8):729-743
pubmed: 34407344
Front Immunol. 2020 Jun 16;11:1392
pubmed: 32612614
Curr Opin Organ Transplant. 2019 Aug;24(4):441-450
pubmed: 31169530
Transplantation. 1999 Aug 27;68(4):480-4
pubmed: 10480403
Nat Med. 2000 Apr;6(4):464-9
pubmed: 10742157
J Clin Immunol. 2014 Jan;34(1):53-7
pubmed: 24217816
Am J Transplant. 2010 Apr;10(4):751-762
pubmed: 20148810
Transplantation. 2020 Jul;104(7):1472-1482
pubmed: 31634324
Am J Transplant. 2021 Sep 22;:
pubmed: 34551187
N Engl J Med. 2008 Jan 24;358(4):353-61
pubmed: 18216355
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155